about
Subtyping of triple-negative breast cancer: implications for therapyHow we manage JAK inhibition in allogeneic transplantation for myelofibrosis.Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.Discerning the clinical relevance of biomarkers in early stage breast cancer.Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.Impact of primary breast cancer therapy on energetic capacity and body compositionPatient-reported outcomes in the Translational Breast Cancer Research Consortium
P50
Q34734477-EFE67A74-8586-4A2D-BCE8-DE585657B7BAQ38254425-9A729521-BA8B-4DE4-A880-AB0F02556FD8Q38291348-A014D4A2-2FFA-4070-88BF-F757DEDB50D4Q38841237-3F22D365-539D-4956-97E6-DD056954C0BBQ55006314-4BCF8E61-E346-47F4-8BD8-6C6BFC619F24Q58716423-8B6D6527-4B2C-4033-8D23-122ACB708610Q91339009-E6E39C58-06DD-4816-BAE5-5EB68312EDBB
P50
description
investigador
@es
professor of clinical medicine
@en
wetenschapper
@nl
name
Tarah J. Ballinger
@af
Tarah J. Ballinger
@an
Tarah J. Ballinger
@ast
Tarah J. Ballinger
@bar
Tarah J. Ballinger
@br
Tarah J. Ballinger
@ca
Tarah J. Ballinger
@co
Tarah J. Ballinger
@cs
Tarah J. Ballinger
@cy
Tarah J. Ballinger
@da
type
label
Tarah J. Ballinger
@af
Tarah J. Ballinger
@an
Tarah J. Ballinger
@ast
Tarah J. Ballinger
@bar
Tarah J. Ballinger
@br
Tarah J. Ballinger
@ca
Tarah J. Ballinger
@co
Tarah J. Ballinger
@cs
Tarah J. Ballinger
@cy
Tarah J. Ballinger
@da
prefLabel
Tarah J. Ballinger
@af
Tarah J. Ballinger
@an
Tarah J. Ballinger
@ast
Tarah J. Ballinger
@bar
Tarah J. Ballinger
@br
Tarah J. Ballinger
@ca
Tarah J. Ballinger
@co
Tarah J. Ballinger
@cs
Tarah J. Ballinger
@cy
Tarah J. Ballinger
@da
P1412
P21
P31
P496
0000-0002-6797-2758